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Abstract
Background: After adoption of artesunate-amodiaquine (AS/AQ) as first-line therapy for the
treatment of uncomplicated malaria by the malaria control programme, this study was designed to
assess the availability of anti-malarial drugs, treatment practices and acceptability of the new
protocol by health professionals, in the urban health facilities and drugstores of Yaoundé city,
Cameroon.
Methods: Between April and August 2005, retrospective and current information was collected
by consulting registers and interviewing health practitioners in urban health facilities using a
structured questionnaire.
Results: In 2005, twenty-seven trade-named drugs have been identified in drugstores; quinine
tablets (300 mg) were the most affordable anti-malarial drugs. Chloroquine was restricted to food
market places and no generic artemisinin derivative was available in public health centres. In public
health facilities, 13.6% of health professionals were informed about the new guidelines; 73.5%
supported the use of AS-AQ as first-line therapy. However, 38.6% apprehended its use due to
adverse events attributed to amodiaquine. Malaria treatment was mainly based on the diagnosis of
fever. Quinine (300 mg tablets) was the most commonly prescribed first-line anti-malarial drug in
adults (44.5%) and pregnant women (52.5%). Artequin® was the most cited artemsinin-based
combination therapy (ACT) (9.9%). Medical sales representatives were the main sources of
information on anti-malarials.
Conclusion: The use of AS/AQ was not implemented in 2005 in Yaoundé, despite the wide range
of anti-malarials and trade-named artemisinin derivatives available. Nevertheless, medical
practitioners will support the use of this combination, when it is available in a paediatric
formulation, at an affordable price. Training, information and participation of health professionals
in decision-making is one of the key elements to improve adherence to new protocol guidelines.
This baseline information will be useful to monitor progress in ACT implementation in Cameroon.
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Background
The greatest number of people exposed to stable transmis-
sion of Plasmodium falciparum lives in sub-Saharan Africa.
In most of the endemic countries, access to appropriate
health care is limited and the problems related to drug
availability and resistance are associated with an increas-
ing mortality rate [1]. In sub-Saharan Africa, chloroquine
has been the base-line drug for the treatment of mild
malaria cases, followed by sulphadoxine-pyrimethamine
as the cheapest second-line drug. However, recent reports
showed that the clinical efficacy of both drugs has signifi-
catively declined [2].
Between 1997 and 2004, twenty-five surveys were conducted
in Cameroon in order to evaluate the therapeutic efficacy of
first-line and second-line anti-malarial treatments, using the
standardized protocol of the World Health Organization
(WHO). Results indicated that chloroquine was no longer
effective in southern and central provinces and presented a
therapeutic failure rate greater than 25% [1]. Sulphadoxine-
pyrimethamine (SP) was associated with failure rates rang-
ing from 8.6% to 14.1%. Amodiaquine remained effective in
the entire country with a failure rate estimate of approxi-
mately 4%, although the drug was used as first-line anti-
malarial therapy from 2002 to 2004.
Recently, WHO proposed modifications of endemic
countries guidelines, changing from monotherapy to
artemisinin-based combination therapy (ACT). In view of
this, and after a scientific consensus meeting held in Janu-
ary 2004, the National Malaria Control Programme of
Cameroon announced that amodiaquine will be replaced
by the combination artesunate-amodiaquine (AS/AQ)
(artesunate 4 mg/kg/day, amodiaquine 10 mg/kg/day).
This combination will be used as first-line therapy for
three days for the treatment of uncomplicated malaria
[3,4]. These guidelines clearly stated that (i) injectable
quinine or injectable artemether would be administered
only in case of drug failure or severe malaria, and (ii)
artemisinin derivatives should not be given to pregnant
women during the first trimester of gestation and quinine
remained the recommended treatment for any malaria
cases during pregnancy. The new treatment guidelines are
based on a clinical (fever) and laboratory (thick blood
smear) diagnosis procedure and recommend an evalua-
tion of treatment efficacy by health professionals, four
days post-treatment [4].
Recommended drugs are provided through the National
Centre for the Provision of Essential Drugs (CENAME),
who signed an agreement with religious health institu-
tions, non-lucrative health units, trade-union of pharma-
cists, and wholesalers of drugs.
Implementation of new treatment guidelines based on the
use of ACT requires the full participation of practitioners
from all health institutions. At the time of the study,
generic artemisinin derivatives were not available at
CENAME. Nevertheless various trade-named anti-malar-
ial drugs were found in private drugstores, especially in
urban areas. The present study reports anti-malarial drug
prescribing practices of medical doctors and nurses, in
urban health facilities in Yaoundé city, central province of
Cameroon, and analyses attitudes and practices one year
after new treatment guidelines based on AS/AQ were
approved by Cameroonian authorities.
Methods
Sites of investigations
This study was conducted in the urban setting of Yaoundé,
in the central province of Cameroon. A total of 23 health
facilities were investigated including two general hospi-
tals, three district hospitals, eight public health centres, 10
private health services and six private drug stores.
Population
A total of 132 health professionals were interviewed
including 31.8% medical doctors, 60.6% nurses and 7.6%
health assistants. 52.3% worked in hospitals and 68.9%
of them belonged to public institutions.
Data collection
All information on anti-malarial drugs available in public
and private health facilities was pooled in order to inves-
tigate drug availability. Information about practices and
behaviours was collected from health professionals using
a structured questionnaire, previously tested and imple-
mented in two health centres. The questionnaire was
divided into four sections including: 1) evaluation of
knowledge and attitudes of medical practitioners accord-
ing to treatment guidelines; 2) current use and regimen of
anti-malarial drugs as first-line and second-line therapy;
3) knowledge and use of artemisinin derivatives; and 4)
sources of information on malaria and anti-malarial
drugs. Additional information was collected from the
health facility's documents and registers.
Data analysis
Responses from interviews were numerically coded and
analysed using Epi-Info version 6.04. Treatment cost
defined in US$ are expressed as a mean. Differences in
proportion were analysed using chi-square test, when
appropriate and significance was set at p < 0.05. This pro-
tocol was approved by the operational research board of
the Ministry of Public Health, in Cameroon.
Results
Availability of anti-malarial drugs
In Yaoundé, up to August 2005, private drugstores could
acquire thirty-two generic-named drugs from CENAME.
The only anti-malarial drug accessible was quinine (tab-
lets 300 mg), representing the first-line drug sold in pri-Malaria Journal 2009, 8:176 http://www.malariajournal.com/content/8/1/176
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vate and public sectors (representing 7% of the total drug
consumption). In addition, three artemisinin-based com-
binations (Arsucam®, Coartem®  and Artequin®) and
twenty-seven trade-named artemisinin derivatives were
available in private drugstores. Chloroquine was mainly
available on food market places.
Knowledge on new treatment guidelines
13.6% of the 132 health professionals were informed
about treatment guidelines and knew that AS/AQ was the
recommended drug for the treatment of uncomplicated
malaria, in Cameroon. Four of them (3.0%) reported hav-
ing the document in their office, at the time of investiga-
tion.
Attitudes related to AS/AQ and treatment guidelines
About three quarters of health professionals supported
the use of AS/AQ as first-line therapy in the new treatment
protocol, while others were in favour of quinine adminis-
tration. However, health professionals mentioned that
restrictions in the use of AS/AQ were based on the follow-
ing parameters: mild to severe adverse events attributed to
amodiaquine (38.6%); risk of non-observance of the
treatment related to the high number of tablets intake (24
pills total for the adult regimen)(28.8%); absence of pae-
diatric formulation (suppositories and oral solutions)
(21.9%); drug cost (6.1%); clinical failures associated
with artesunate used in monotherapy for three days
(4.6%).
Practices regarding malaria diagnosis
The first-line treatment of malaria was administered fol-
lowing a clinical diagnosis based upon the presence of
fever by three quarters of the practitioners. In addition, a
thin or thick blood smear examination could be per-
formed before treatment; however laboratory results were
obtained after drug prescription and administration.
Anti-malarial drugs used as first-line treatment
Quinine (300 mg tablets) was the most commonly pre-
scribed anti-malarial drug in adults (44.5%) and pregnant
women (52.5%) (Table 1). For children, 62.8% of the pre-
scribers were in favour of oral suspensions of amodi-
aquine alone while 4.6% of the physicians administered
the recommended AS/AQ (Arsucam®) combination ther-
apy to adults and 1.5% to children. Artemether-lumefan-
trine (Coartem®) was the most used form of ACT (8.3% in
adults). Health workers prescribed suppositories of
artesunate (Plasmotrim®) (3.8%) and tablets of dihy-
droartemisinin (Cotecxin®) (2.3%) to pregnant women,
but the prescription of AS/AQ (Arsucam®) was not
reported in this group. There were no significant differ-
ences between prescription of proper dosage and drug reg-
imens.
Anti-malarial drugs used as second-line treatment
In case of clinical failure, about 90% of the practitioners
intended to prescribe a laboratory diagnosis before
administration of a second-line treatment. The propor-
tion of second-line therapy showed that injectable qui-
nine (intramuscular) was the first-line anti-malarial drug
prescribed in adults (43.2%), pregnant women (53.7%)
and children (36.4%) (Table 2). Intra-muscular injectable
formulations were prescribed, with a mean treatment
schedule of two injections per day for two days. The sec-
ond drug of choice was quinine in the form of tablets of
300 mg, in adults (20.4%) and pregnant women (19.7%),
and as an oral solution in children (13.6%). According to
guideline recommendations, injectable artemether was
prescribed in adults (3.0%), pregnant women (1.5%) and
under five children (3.8%). Other artemisinin derivatives
were prescribed as second-line drugs, such as artesunate
suppositories (18.1%), Cotecxin®  (10.6%), Artequin®
(9.8%), Coartem®  (3%), Artesiane®  (2.3%). Only one
health professional prescribed antibiotics associated with
anti-malarial drugs, to cover for other infections.
Attitudes and practices related to artemisinin derivatives
The evaluation of knowledge about artemisinin deriva-
tives indicated that 5.3% of the nurses (7 nurses) reported
receiving no information related to these drugs (Table 3).
On the other hand, trade-named anti-malarial drugs con-
Table 1: Anti-malarial drugs used as first-line treatment by medical practitioners
Drugs prescribed by 132 clinicians Adults
N = 128(%)
Pregnant women n = 124 (%) Under five children
n = 126 (%)
AS/AQ 4.6 0.0 1.5
Quinine tablets 44.5 52.3 15.9
Amodiaquine 20.4 28.0 62.8
Artemether-lumefantrine 8.3 0.0 2.4
Artesunate-mefloquine 1.5 0.0 0.8
Artesunate suppositories 7.6 3.8 5.3
Dihydroartemisinin 5.3 2.3 4.6
Halofantrine 0.0 0.0 1.5
Sulphadoxine/Pyrimethamine 5.8 3.8 0.0
Pyrimethamine alone 0.0 0.8 0.0
Injectable quinine 3.0 9.0 4.5
Injectable artemether 0.8 0.0 2.0Malaria Journal 2009, 8:176 http://www.malariajournal.com/content/8/1/176
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taining artemether (42.4%) or dihydroartemisinin
(19.7%) were the well known and the most frequently
cited drugs. The first combination therapy being Artequin®
(9.9%) and Coartem® (7.6%) followed by the less cited
Arsucam® (7%), a co-formulation of artesunate-amodi-
aquine. 84.1% of the health professionals knew that these
anti-malarial drugs should not be administered in preg-
nant women during the first trimester of gestation.
Half of the health practitionners selected artemisinin
derivatives because they believed these drugs were more
effective than the currently used monotherapies, with lim-
ited adverse events (17.4%) compared to amodiaquine
(Table 4). About 15% of the practitioners mentioned that
observance of the treatment regimen is an important
parameter. The choice of the prescription was also based
on the following criteria: drug cost (10.6%), trade-named
advertised drugs (4.5%) and patient's request (1.5%).
A total of 70.5% of the health professionals reported that
they received the main source of information from medi-
cal visitors employed by pharmaceutical companies
(Table 5).
Discussion
The implementation of new treatment regimens faces sev-
eral constraints, such as drug availability, drug cost and
rational use. Moreover, in urban areas, the wild range of
concurring anti-malarial drugs offered by the private sec-
tor represents the main limitations. Our investigation
indicated that the first line combination therapy AS/AQ
was not available at the national office of drug manage-
ment at the time of the study. On the other hand, stocks
of quinine tablets were available in both public and pri-
vate drugstores and a large choice of anti-malarial drugs
was offered by private drug stores, including artemisinin
derivatives alone or proposed as co-blisters with amodi-
aquine or other anti-malarial drugs.
In addition, ACT is more expensive than chloroquine, SP
or amodiaquine used in monotherapy, and improper and
abusive use without proper diagnosis will have a direct
clinical and economic impact [5-7]. Parasitological diag-
nosis of malaria is an important parameter leading to the
appropriate use of anti-malarial drugs. The results of this
study demonstrate that the diagnosis of malaria was
Table 2: Anti-malarial drugs used as second-line treatment by medical practitioners
Drugs prescribed by 132 clinicians Adults
N = 124 (%)
Pregnant women n = 113 (%) Under five children
N = 122 (%)
Injectable quinine 43.2 53.7 36.4
Injectable Artemether 3.0 1.5 3.8
AS/AQ 2.3 3.0 2.3
Artesunate-mefloquine 9.8 0.8 3.8
Artemether-lumefantrine 3.0 0.0 0.8
Quinine (oral) 20.4 19.7 13.6
Amodiaquine 0.8 1.5 6.0
Artesunate suppositories 10.6 5.3 18.1
Dihydroartemisinin 3.0 7.6 10.6
Artemether, oral 0.0 1.5 2.3
Halofantrine 0.8 0.0 0.0
Injectable Sulphadoxine/Pyrimethamine 2.3 3.8 1.5
Sulphadoxine/Pyrimethamine 0.0 0.8 0.0
Quinine + antibiotics 0.0 0.8 0.8
Table 3: Artemisinin derivatives known by medical practitioners 
in urban zones
Artemisinin derivatives Medical practitioners
(n = 132), Percent
Informed (n = 125)
Monotherapies
Artesunate suppositories (56) 42.4
Dihydroartemisinin (26) 19.7
Artemether (11) 8.3
Bitherapies (ACT)
Artesunate-mefloquine (13) 9.9
Artemether-lumefantrine (10) 7.6
Artesunate-amodiaquine (9) 6.8
Not informed (n = 7)
Table 4: Main selection criteria of artemisinin derivatives 
according to prescribers
Selection criteria Medical practitioners
(n = 132), Percent
Therapeutic efficacy (67) 50.8
Few adverse events (23) 17.4
Observance (few tablets) (20) 15.2
Drug cost (lowest price) (14) 10.6
Drug names (6) 4.5
Patient's request (2) 1.5Malaria Journal 2009, 8:176 http://www.malariajournal.com/content/8/1/176
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mainly based on the presence of fever without further par-
asitological investigation. Such findings have been previ-
ously reported from many endemic countries and are no
longer surprising [5]. The absence of parasitological diag-
nosis is based on (i) lack of laboratory equipment and
quality control to ensure reliable results, on the sites of
investigations, (ii) cost of diagnosis which increases con-
sultation and drug expenses, and (iii) the assumption that
fever is mainly related to malaria in most endemic coun-
tries. However, malaria control efficacy in low transmis-
sion settings, such as urban areas implies the use of
malaria parasite detection [8].
The present study highlighted problems related to the
implementation of ACT in Cameroon, including the lack
of protocol guidelines and in-service training related to
malaria treatment, as previously reported in Sudan [9]
and Kenya [10]. The lack of awareness and information
was an important criterion explaining the non-adherence.
Most of health workers supported the use of AS/AQ if the
drug is made available in proper formulations such as few
tablets for adults and pregnant women, and oral (liquid)
or rectal formulations for children. Because it is proposed
as a syrup formulation, amodiaquine used in mono-
therapy was the first-line treatment in children. This
behaviour is contradictory to the list of adverse events
attributed to amodiaquine, and reported by adult patients
and practitioners. Therefore, the adaptation of proper
drug formulations appears to be a crucial treatment allo-
cation factor.
The observations made during this survey have high-
lighted the lack of information regarding the transition
from monotherapy to artemisinin-based combination
therapies, as previously described in Zambia [11].
Furthermore, the availability of quinine tablets at low
price, in routine prescription and the improper use of
injectable forms could compromise the treatment of
severe malaria. Quinine has already been identified as the
most prescribed anti-malarial drug in Cameroon [12]. The
present study revealed that the wide range of artemisinin
derivatives used in monotherapy, especially paediatric
forms, influenced the prescribing patterns of medical
practitioners. Given the wide range of anti-malarial drugs
offered in urban areas, and conflicting information given
mainly by private medical visitors, a strong implementa-
tion of official sources of information is needed in order
to promote suitable clinical practices and ensure proper
and rational use of anti-malarial drugs.
The present study conducted in mid-2005 indicates that
the use of AS/AQ was not implemented in urban areas of
Yaoundé in Cameroon, and that the wide range of anti-
malarials and trade-named artemisinin derivatives were
not yet accepted by the practitioners. However, medical
practitioners will support the use of the AS/AQ combina-
tion for the treatment of uncomplicated malaria, expect-
ing that the drug will be properly formulated (paediatric
forms, reduced number of pills to take) and offered at
lower price. Training, information and participation of
health professionals to decision making is a key to
improve adherence to new protocol guidelines. Results
from this study and other investigations conducted in
other countries highlight the need to consider specific
implementation guidelines, since most African countries
have now adopted ACT. Beside drug availability, the
acceptance of ACT by health professionals and the overall
population should be considered early enough given pre-
vious and current practices and use of available anti-
malarial drugs.
The situation had improved in 2007. Following WHO rec-
ommendations, a public release of the Cameroonian Min-
istry of Public Health announced that all anti-malarial
drugs available in monotherapy should not be sold and
used anymore in health facilities. Therefore, nationwide
withdrawal of these drugs was performed in public and
private pharmacies and drugstores, starting in January
2007. This measure might prove efficient if (1) the recom-
mended AS/AQ formulation will be made available at the
national level with adapted paediatric formulations, and
(2) if the reasons why monotherapies are not recom-
mended anymore are clearly explained to the overall pop-
ulation.
Furthermore, in February 2007, the cost of malaria treat-
ment was officially reduced to 0.30 US$ and 1.3 US$ (1$
= 483 CFA, May 2008) in public health facilities, followed
in April 2007 by private hospitals and pharmacies to reach
a price between 0.48 US$ and 2.06 US$. The move by gov-
ernment to subsidize the cost of treating malaria should
improve anti-malarial drug accessibility to the overall
population.
Conclusion
The use of AS/AQ was not implemented in 2005 in
Yaoundé, despite the wide range of anti-malarials and
trade-named artemisinin derivatives available. Neverthe-
less, medical practitioners are prepared to support the use
Table 5: Main sources of information in urban health facilities
Sources of information Medical practitioners
(n = 132) Percent
Medical visitors (93) 70.5
Health personnel (17) 12.9
Medias (Radio, TV) (9) 6.8
Ministry of public health (9) 6.8
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of this combination, once it becomes available in a paedi-
atric formulation, at an affordable price. Training, infor-
mation and participation of health professionals in
decision-making is one of the key elements to improve
adherence to new protocol guidelines. Reporting data
from the introduction of ACT could provide useful infor-
mation to highlight the strength and weaknesses of ACT
implementation programmes. Indicators from this study
could be considered as the starting point for further eval-
uation of the availability and accessibility of ACT in Cam-
eroon.
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